Prognostic significance of preoperative prognostic nutritional index in ovarian cancer

Dai, Yan; Liu, Mingbo; Li, Lei; Lu, Shentao

doi:10.1097/md.0000000000021840

Cited by 26 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For OC, the pooled HR for OS and PFS was 1.28 (0.73-2.26) and 1.82 (1.41-2.36), respectively. These findings were validated by a recently published metaanalysis (45). For CC, the pooled HR for OS and PFS was 2.96 (1.87-4.70) and 2.54 (1.41-4.58), respectively.…”

Section: Gynecological Cancerssupporting

confidence: 66%

Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review

Li¹,

Nakamura²,

Casadei-Gardini³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Objective: To perform a narrative review of the prognostic value of prognostic nutritional index (PNI) in cancers.Background: Prognostic estimation greatly determines the treatment approach in various cancers. The prognostic nutritional index (PNI), calculated using the serum albumin level and total lymphocyte count, is a useful indicator to assess nutritional and immunological conditions. The PNI represents a low-cost, easy-toperform, noninvasive, rapid, and standardized tool for estimating the prognosis of cancer. Many studies have aimed to clarify the prognostic value of PNI for various types of cancer. Methods:We summarize the studies, particularly the systematic reviews and meta-analyses, that have examined the prognostic value of PNI in common cancers. Conclusions:The relevant studies indicate that low PNI is an independent prognostic factor for decreasing overall survival in many types of cancers. Disease-free survival and progression-free survival were also associated with PNI in some types of cancer including lung cancer and renal cell carcinoma. Therefore, we suggest that the measurement of PNI is a useful method to identify cancer patients that have a worse prognosis and that the treatment strategy for these patients be adjusted accordingly. We hypothesize that maintaining good nutritional status during treatment may improve outcomes of various cancers.

show abstract

Section: Gynecological Cancerssupporting

confidence: 66%

Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review

Li¹,

Nakamura²,

Casadei-Gardini³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…The mechanism by which a low nutritional status decreases the survival time of breast cancer patients is still not sufficiently understood. The PNI, as a systemic immune–nutrition index based on the peripheral lymphocyte count and serum albumin levels, represents the immune and nutritional status and is also a significant biomarker for many tumors ( Dai et al, 2020 ; Hao et al, 2020 ; Zhang et al, 2020 ). The PNI was initially developed to evaluate the postoperative complications in patients who received gastrointestinal surgery ( Onodera et al, 1984 ).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator

Chen

Bai

Kong

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

ObjectivePrognostic nutritional index (PNI), calculated as serum albumin (ALB) (g/L) + 5 × total lymphocyte count (109/L), is initially used to evaluate nutritional status in patients undergoing surgery and may evaluate the therapeutic effects and predict the survival of various solid tumors. The present study aimed to evaluate the potential prognostic significance of PNI in breast cancer patients receiving neoadjuvant chemotherapy (NACT).MethodsA total of 785 breast cancer patients treated with neoadjuvant chemotherapy were enrolled in this retrospective study. The optimal cutoff value of PNI by receiver operating characteristic curve stratified patients into a low-PNI group (<51) and a high PNI group (≥51). The associations between breast cancer and clinicopathological variables by PNI were determined by chi-square test or Fisher’s exact test. Kaplan–Meier plots and log-rank test were used to evaluate the clinical outcomes of disease-free survival (DFS) and overall survival (OS). The prognostic value of PNI was analyzed by univariate and multivariate Cox proportional hazards regression models. The toxicity of NACT was accessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC).ResultsThe results indicated that PNI had prognostic significance by an optimal cutoff value of 51 on DFS and OS in univariate and multivariate Cox regression survival analyses. Breast cancer patients with a high PNI value had longer DFS and OS than those with a low PNI value [47.64 vs. 36.60 months, P < 0.0001, hazard ratio (HR) = 0.264, 95%CI = 0.160–0.435; 73.61 vs. 64.97 months, P < 0.0001, HR = 0.319, 95%CI = 0.207–0.491, respectively]. Furthermore, the results indicated that patients with high PNI had longer DFS and OS than those with low PNI in early stage and advanced breast cancer, especially in advanced breast cancer. The mean DFS and OS times for breast cancer patients with high PNI by the log-rank test were longer than in those with low PNI in different molecular subtypes. Moreover, the mean DFS and OS times in patients with high PNI by the log-rank test were longer than in those patients with low PNI without or with lymph vessel invasion. The common toxicities after neoadjuvant chemotherapy were hematologic and gastrointestinal reaction, and the PNI had no significance on the toxicities of all enrolled patients, except in anemia, leukopenia, and myelosuppression.ConclusionPretreatment PNI with the advantages of being convenient, noninvasive, and reproducible was a useful prognostic indicator for breast cancer patients receiving neoadjuvant chemotherapy and is a promising biomarker for breast cancer on treatment strategy decisions.

show abstract

“…Numerous inflammatory biomarkers, such as neutrophils, lymphocytes, platelets and so on, had been implied as the prognostic predictor for different cancers. 21–23 In osteosarcoma, some researchers revealed that lymphocyte-to-monocyte ratio (LMR) was positively related to overall and event-free survival rates of patients, while the neutrophil-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) showed the opposite trends. 24–26 Several studies also implied that nonsteroidal anti-inflammatory drugs (NSAIDs) could inhibit the progression of osteosarcoma.…”

Section: Discussionmentioning

confidence: 99%

Exploration and Validation of a Novel Inflammatory Response-Associated Gene Signature to Predict Osteosarcoma Prognosis and Immune Infiltration

Fu¹,

He²,

Liu³

et al. 2021

JIR

View full text Add to dashboard Cite

Background Inflammatory response took part in the progression of tumor and was regarded as the hallmark of cancer. However, the prognostic relationship between osteosarcoma and inflammatory response-associated genes (IRGs) was unclear. This research aimed to explore the correlations between osteosarcoma prognosis and IRG signature. Methods The inflammatory response-associated differentially expressed messenger RNAs (DEmRNAs) were screened out through Gene Expression Omnibus (GEO) and Molecular Signature Database (MSigDB) databases. Univariate and multivariate cox regression analyses were utilized to construct the IRG signature. The prognostic value of signature was investigated through Kaplan–Meier (KM) survival curve and nomogram. DEmRNAs among high and low inflammatory response-associated risks were identified and functional enrichment analyses were conducted. ESTIMATE, CIBERSORT and single-sample gene set enrichment analyses (ssGSEA) were implied to reveal the alterations in immune infiltration. All the above results were validated in Target database. The expression of IRGs was also validated in different cell lines by quantitative real-time PCR (qRT-PCR) and osteosarcoma patient samples by immunohistochemistry. Results The IRG signature that consisted of two genes (MYC, CLEC5A) was established. In training and validation datasets, patients with lower risk scores survived longer and the IRG signature was confirmed as the independent prognostic factor in osteosarcoma. The nomogram was constructed and the calibration curves demonstrated the reliability of this model. Functional analysis of risk score-associated DEmRNAs indicated that immune-related pathways and functions were significantly enriched. ssGSEA revealed that 14 immune cells and 11 immune functions were significantly dysregulated. The qRT-PCR results indicated IRGs were significantly differently expressed in osteosarcoma and osteoblast cell lines. The immunohistochemistry analyses of patients’ samples revealed the same result. Conclusion The novel osteosarcoma inflammatory response-associated prognostic signature was established and validated in this study. This model could serve as the biomarker and therapeutic target for osteosarcoma in the future.

show abstract

Prognostic significance of preoperative prognostic nutritional index in ovarian cancer

Cited by 26 publications

References 26 publications

Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review

Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review

Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator

Exploration and Validation of a Novel Inflammatory Response-Associated Gene Signature to Predict Osteosarcoma Prognosis and Immune Infiltration

Contact Info

Product

Resources

About